{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T11:06:53Z","timestamp":1775041613623,"version":"3.50.1"},"reference-count":26,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T00:00:00Z","timestamp":1640563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Wet age-related macular degeneration (wAMD) is a chronic, progressive disease of the central part of the retina. Standard treatment for wAMD consists of multiple intravitreal injections of anti-vascular endothelial growth factor drugs. The study goal was to evaluate the three-year effectiveness of wAMD treatment with aflibercept and ranibizumab as part of the therapeutic program in routine clinical practice. Materials and Methods: 1430 patients (possessing 1430 wAMD eyes) with median age of 78.0 years (71.0, 83.0) were enrolled in a non-randomized, retrospective, observational, multicenter study; 804 (56.2%) eyes were treatment-na\u00efve. Therapy was carried out in accordance with the guidelines of the treatment program (the fixed or pro re nata regimen). Results: After the first year of treatment, there was a gain of 2.03 (12.15) letters; after the second, 0.94 (13.72) (p \u02c2 0.001); and after the third, 0.17 (14.05) (p \u02c2 0.001). There was a significant reduction in the central retinal thickness. In the first year, the patients received 7.00 (5.00, 8.00) injections. In the following years, a significantly lower number of injections (4.00 (2.00, 5.00)) was administered. After the first year, there was a significant difference in the distribution of the best corrected visual acuity according to the Early Treatment Diabetic Retinopathy Study protocol, with more frequent values in the ranges &gt; 35 \u2264 70 for this parameter and &gt; 70 letters in the treatment na\u00efve eye subgroup. After the first year, central retinal thickness in treatment-na\u00efve eyes was significantly reduced. Conclusions: Regular treatment of wet age-related macular degeneration as part of the treatment program achieves functional stabilization and significant morphological improvement over a long-term, three-year follow-up, with significantly fewer injections needed after the first year of treatment.<\/jats:p>","DOI":"10.3390\/medicina58010042","type":"journal-article","created":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T01:20:43Z","timestamp":1640654443000},"page":"42","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Three-Year Outcomes of Wet Age-Related Macular Degeneration Treatment in Polish Therapeutic Programs"],"prefix":"10.3390","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6366-802X","authenticated-orcid":false,"given":"Ma\u0142gorzata","family":"Figurska","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Military Institute of Medicine, The Central Clinical Hospital of the Ministry of National Defense, 04-141 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"R\u0119kas","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Military Institute of Medicine, The Central Clinical Hospital of the Ministry of National Defense, 04-141 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,27]]},"reference":[{"key":"ref_1","first-page":"194","article-title":"One year outcomes of wet age-related macular degeneration treatment with aflibercept in therapeutic program","volume":"121","author":"Figurska","year":"2019","journal-title":"Klin. Oczna"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1177\/1120672119874598","article-title":"One-year outcomes of the Polish treatment program for the wet form of age-related macular degeneration using intravitreal therapy","volume":"30","author":"Figurska","year":"2020","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_3","first-page":"65","article-title":"Program lekowy \u201cLeczenie neowaskularnej (wysi\u0119kowej) postaci zwyrodnienia plamki zwi\u0105zanego z wiekiem\u201d w Polsce\u2013od kwalifikacji do leczenia","volume":"19","author":"Figurska","year":"2016","journal-title":"Okulistyka"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/17425247.2016.1213240","article-title":"Current advances in the treatment of neovascular age-related macular degeneration","volume":"14","author":"Villegas","year":"2017","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1167\/iovs.04-0601","article-title":"Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration","volume":"46","author":"Gaudreault","year":"2005","journal-title":"Investig. Opthalmology Vis. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","article-title":"Intravitreal aflibercept injection for neovascular age-related macular degeneration: Ninety-six-week results of the VIEW studies","volume":"121","author":"Kaiser","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.ophtha.2015.08.014","article-title":"Scheduled versus Pro Re Nata Dosing in the VIEW Trials","volume":"122","author":"Richard","year":"2015","journal-title":"Ophthalmology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.oret.2017.01.004","article-title":"Long-term Safety and Visual Outcome of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration: VIEW 1 Extension Study","volume":"4","author":"Kaiser","year":"2017","journal-title":"Ophthalmol. Retina"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/IAE.0b013e3181d87e04","article-title":"Novel method for analyzing Snellen visual acuity measurements","volume":"30","author":"Gregori","year":"2010","journal-title":"Retina"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ophtha.2015.09.039","article-title":"First Year Visual Acuity Outcomes in the United Kingdom of Providing Aflibercept According to the VIEW Study Protocol for Age-Related Macular Degneration","volume":"123","author":"Talks","year":"2016","journal-title":"Ophthalmology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.oret.2017.09.017","article-title":"Aflibercept for Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in Germany: Twelve-Month Outcomes of PERSEUS","volume":"2","author":"Framme","year":"2018","journal-title":"Ophthalmol. Retina"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00417-020-04803-8","article-title":"Importance of continuous treatment with intravitreal aflibercept injections in patients with neovascular age-related macular degeneration-12-month post hoc analysis of the PERSEUS real-world evidence study","volume":"259","author":"Wachtlin","year":"2021","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/eye.2017.6","article-title":"One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular agerelated macular degeneration","volume":"31","author":"Almuhtaseb","year":"2017","journal-title":"Eye"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Weber, M., Dominguez, M., Coscas, F., Faure, C., Baillif, S., Kodjikian, L., and Cohen, S.-Y. (2020). Impact of intravitreal aflibercept dosing regimens in treatment-na\u00efve patients with neovascular age-related macular degeneration: 2-year results of RAINBOW. BMC Ophthalmol., 20.","DOI":"10.1186\/s12886-020-01468-z"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1007\/s00417-021-05073-8","article-title":"PERSEUS 24-month analysis: A prospective non-interventional study to assess the effectiveness of intravitreal aflibercept in routine clinical practice in Germany in patients with neovascular age-related macular degeneration","volume":"259","author":"Eter","year":"2021","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s40123-018-0139-5","article-title":"Three-Year Outcomes of Aflibercept Treatment for Neovascular Age-Related Macular Degeneration: Evidence from a Clinical Setting","volume":"7","author":"Eleftheriadou","year":"2018","journal-title":"Ophthalmol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group (2014). The neovascular age-related macular degeneration database: Multicenter study of 92 976 ranibizumab injections: Report 1: Visual acuity. Opthalmology, 121, 1092\u20131101.","DOI":"10.1016\/j.ophtha.2013.11.031"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41433-020-0851-y","article-title":"Impact of injection frequency on 5-year real-world visual acuity outcomes of aflibercept therapy for neovascular age-related macular degeneration","volume":"35","author":"Chandra","year":"2021","journal-title":"Eye"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/aos.14183","article-title":"Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration","volume":"98","author":"Brynskov","year":"2020","journal-title":"Acta Ophthalmol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1038\/s41433-020-0764-9","article-title":"Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration","volume":"34","author":"Chandra","year":"2020","journal-title":"Eye"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ajo.2016.09.038","article-title":"Long-Term Outcomes of Aflibercept Treatment for Neovascular Age-Related Macular Degeneration in a Clinical Setting","volume":"174","author":"Eleftheriadou","year":"2017","journal-title":"Am. J. Ophthalmol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/IAE.0000000000001496","article-title":"Two year outcomes of \u201cTreat and Extend\u201d intravitreal therapy using aflibercept preferentially for neovascular age-related macular degeneration","volume":"38","author":"Barthelmes","year":"2018","journal-title":"Retina"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.oret.2019.01.018","article-title":"Long-term Outcome of Intravitreal Aflibercept Treatment for Neovascular Age-Related Macular Degeneration Using a \u201cTreat-and-Extend\u201d Regimen","volume":"3","author":"Traine","year":"2019","journal-title":"Ophthalmol. Retina"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/eye.2016.90","article-title":"Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: An instrumental variable analysis of the AURA study","volume":"30","author":"Holz","year":"2016","journal-title":"Eye"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1136\/bjophthalmol-2013-303232","article-title":"Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme","volume":"97","author":"Holz","year":"2013","journal-title":"Br. J. Ophthalmol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/1\/42\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:54:19Z","timestamp":1760169259000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/1\/42"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,27]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["medicina58010042"],"URL":"https:\/\/doi.org\/10.3390\/medicina58010042","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,27]]}}}